"Antagonism of the VIP Signaling Pathway" in Patent Application Approval Process (USPTO 20230293681).
In: Vaccine Weekly, 2023-10-13, S. 159-159
serialPeriodical
Zugriff:
The Human T-lymphotropic virus Type I (HTLV-1) vaccine, Friend spleen focus-forming virus (SFFV) vaccine, and Xenotropic MuLV-Related Virus (XMRV) vaccine. In some embodiments, the subject is diagnosed with a virus that is double stranded DNA virus, sense single stranded DNA virus, double stranded RNA virus, sense single stranded RNA virus, antisense single stranded RNA virus, sense single stranded RNA retrovirus or a double stranded DNA retrovirus. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Antagonism of the VIP Signaling Pathway" in Patent Application Approval Process (USPTO 20230293681).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2023-10-13, S. 159-159 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|